The Food and Drug Administration on Friday approved AstraZeneca PLC's Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.
The drug has been on the market since 2014 for ovarian cancer, and is the first in a new class of medicines called PARP inhibitors to be approved for breast cancer.
Until recently, cancer medicines targeted the disease based on where in the body it occurs.
About 20 percent to 25 percent of patients with hereditary breast cancers have a BRCA mutation.
Common side effects include nausea, fatigue, respiratory infections and blood count problems.